Prelude Therapeutics Azioni (NASDAQ: PRLD)

Ultime notizie per Prelude Therapeutics (NASDAQ:PRLD) Azioni

Prelude Therapeutics

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics Inc

AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) sees Q4 sales of $685.000 million-705.000 million vs $667.95 million estimate.

News

Guidance

AMN Healthcare Services Sees Q4 Sales $685.000M-705.000M vs $667.95M Est

The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $0.01 by 3100 percent. The company reported quarterly sales of $193.975 million which missed the analyst consensus estimate of $215.463 million by 9.97 percent. This is a 152.30 percent increase over sales of $76.884 million the same period last year.

Earnings

Earnings Misses

STKS

The One Group Hospitality Q3 2024 Adj. EPS $(0.30) Misses $0.01 Estimate, Sales $193.975M Miss $215.463M Estimate

Saul Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFS#NYSE">BFS</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.43 by 11.63 percent. The company reported quarterly sales of $67.30 million which beat the analyst consensus estimate of $65.78 million by 2.31 percent. This is a 5.54 percent increase over sales of $63.77 million the same period last year.

Earnings Beats

Saul Centers Q3 2024 GAAP EPS $0.48 Beats $0.43 Estimate, Sales $67.30M Beat $65.78M Estimate

WIIM

BILL

BILL Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 guidance above estimates

LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 52.94 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $74.244 million which beat the analyst consensus estimate of $71.127 million by 4.38 percent. This is a 26.73 percent decrease over sales of $101.332 million the same period last year.

LPSN

LivePerson Q3 2024 GAAP EPS $(0.32) Misses $(0.22) Estimate, Sales $74.244M Beat $71.127M Estimate

ADEA

Adeia Files Multiple Patent Infringement Lawsuits Against Disney, Hulu, And ESPN In U.S. And Europe; Legal Actions Initiated In Delaware And Across European Courts

NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.30) by 100 percent. This is a 95.42 percent increase over losses of $(13.11) per share from the same period last year. The company reported quarterly sales of $2.44 million which missed the analyst consensus estimate of $2.62 million by 6.94 percent. This is a 1.61 percent decrease over sales of $2.48 million the same period last year.

NovaBay Pharmaceuticals Q3 EPS $(0.60) Misses $(0.30) Estimate, Sales $2.44M Miss $2.62M Estimate

Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 16.67 percent. The company reported quarterly sales of $102.073 million which missed the analyst consensus estimate of $102.718 million by 0.63 percent. This is a 4.69 percent decrease over sales of $107.095 million the same period last year.

UEIC

Universal Electronics Q3 2024 Adj. EPS $0.10 Misses $0.12 Estimate, Sales $102.073M Miss $102.718M Estimate

BNED

Barnes & Noble Education Sees Prelim Q2 First Day Program Revenue $235M

Metallus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTUS#NYSE">MTUS</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.02) by 350 percent. The company reported quarterly sales of $227.200 million which missed the analyst consensus estimate of $274.367 million by 17.19 percent. This is a 35.86 percent decrease over sales of $354.200 million the same period last year.

MTUS

Metallus Q3 2024 Adj. EPS $(0.09) Misses $(0.02) Estimate, Sales $227.200M Miss $274.367M Estimate

ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent.

LOGC

ContextLogic Q3 2024 GAAP EPS $(0.04) Misses $(0.01) Estimate

Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(0.98) by 3.06 percent. This is a 35.71 percent decrease over losses of $(0.70) per share from the same period last year.

PLRX

Pliant Therapeutics Q3 EPS $(0.95) Beats $(0.98) Estimate

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $36.325 million which beat the analyst consensus estimate of $35.609 million by 2.01 percent. This is a 7.39 percent decrease over sales of $39.222 million the same period last year.

ONTF

ON24 Q3 2024 Adj. EPS $0.02 Beats $0.00 Estimate, Sales $36.325M Beat $35.609M Estimate

Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(1.11) by 8.11 percent. The company reported quarterly sales of $24.564 million which missed the analyst consensus estimate of $26.657 million by 7.85 percent. This is a 32.57 percent decrease over sales of $36.427 million the same period last year.

SKLZ

Skillz Q3 2024 GAAP EPS $(1.20) Misses $(1.11) Estimate, Sales $24.564M Miss $26.657M Estimate

Management

Eventbrite Appoints Anand Gandhi As CFO, Effective Nov. 19; Lanny Baker Shifts Focus To COO Role To Drive Operational Excellence And Growth

Transcontinental Realty Q3 EPS $0.20 Down From $0.52 YoY, Sales $11.607M Down From $12.525M YoY

Olo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 50 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $71.853 million which beat the analyst consensus estimate of $70.940 million by 1.29 percent. This is a 24.33 percent increase over sales of $57.794 million the same period last year.

Olo Q3 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $71.853M Beat $70.940M Estimate

Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. The company reported quarterly sales of $10.867 million which missed the analyst consensus estimate of $12.091 million by 10.12 percent. This is a 36.78 percent decrease over sales of $17.190 million the same period last year.

TACT

Transact Technologies Q3 2024 GAAP EPS $(0.06) Beats $(0.08) Estimate, Sales $10.867M Miss $12.091M Estimate

UPST

Upstart Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.41) by 151.22 percent. This is a 160 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $71.75 million which beat the analyst consensus estimate of $16.27 million by 340.98 percent. This is a 667.19 percent increase over sales of $9.35 million the same period last year.

PSTX

Poseida Therapeutics Q3 EPS $0.21 Beats $(0.41) Estimate, Sales $71.75M Beat $16.27M Estimate

Prelude Therapeutics (PRLD) announced the presentation of additional data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a ...

Prelude Therapeutics presents new data from Phase 1 trial of PRT3789

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report), with a pric...

Buy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial Position

Jeffrey Hung, an analyst from Morgan Stanley, maintained the Sell rating on Prelude Therapeutics (PRLD – Research Report). The associated price tar...

Cautious Outlook on Prelude Therapeutics: Sell Rating Amid Modest Trial Results and Market Skepticism

Analyst Peter Lawson of Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), reducing the price target to $1.00. Pet...

Prelude Therapeutics: Sell Rating Due to Limited Efficacy Improvement and Financial Challenges

Barclays analyst Peter Lawson lowered the firm's price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an Underweight rating on the s...

Prelude Therapeutics price target lowered to $1 from $3 at Barclays

Prelude Therapeutics (PRLD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns fr...

Optimism in Prelude Therapeutics: Buy Rating Backed by Promising PRT3789 Trial Results

"Our third quarter was marked by dedicated execution and the achievement of essential milestones for our lead clinical programs targeting SMARCA2,"...

Prelude Therapeutics reports Q3 EPS (43c), consensus (47c)

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price target at ...

Prelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy Rating

Prelude Therapeutics GAAP EPS of -$0.43, revenue of $3M

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a pric...

Prelude Therapeutics (PRLD) Gets a Sell from Morgan Stanley

PRLD

Press Releases

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Health Care

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Comments

Prelude Therapeutics

Notizie

Ultime notizie per Prelude Therapeutics (NASDAQ:PRLD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO